Biocon is currently trading at Rs. 642.00, up by 1.60 points or 0.25% from its previous closing of Rs. 640.40 on the BSE.
The scrip opened at Rs. 649.80 and has touched a high and low of Rs. 650.40 and Rs. 638.80 respectively. So far 16958 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 718.35 on 26-Sep-2018 and a 52 week low of Rs. 365.25 on 14-Nov-2017.
Last one week high and low of the scrip stood at Rs. 650.40 and Rs. 624.45 respectively. The current market cap of the company is Rs. 38424.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.94% and 17.38% respectively.
United States Food and Drug Administration (USFDA) has conducted a pre-approval inspection of Biocon’s new Oral Solid Dosage Forms manufacturing facility at Bengaluru from November 05 to 09. The audit concluded without any observations and no Form 483 was issued.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
